Sep 03, 2021

CDC slide #7 reports 20 times higher myopericarditis than baseline for 18-24 year old males,

Aug 2021 study from Yale, John Hopkins, Stanford, UCSF and others,

> 63 patients with a mean age of 15.6 years were included. 92% were male. All had received an mRNA vaccine and, except for one, presented following the 2nd dose. Four patients had significant dysrhythmia. 14% had mild left ventricular dysfunction on echocardiography which resolved on discharge. 88% met the diagnostic cardiac magnetic resonance (CMR) Lake Louise criteria for myocarditis.

Aug 23, 2021

Children and pregnant women are the two sub-populations I mentioned previously.

> Given that COVID-19 disease is far milder in the majority of children than in adults, the risk–benefit of a pediatric SARS-CoV-2 vaccine must be carefully weighed [0]

> The prognostic significance, long-term implications and mechanism of this myocardial injury needs to be studied further, especially as vaccination efforts are rolled out to younger children. [1]

> While the safety, immunogenicity, and efficacy data for the 4 authorized vaccines are reassuring so far, none of these vaccines has been systematically studied in pregnant and breastfeeding people [2]

> it is important to remain transparent about the lack of information, acknowledge concerns, and support those who decide to defer vaccination until more data are available [2]

[0] SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges (Feb 2021)

[1] COVID-19 Vaccination-Associated Myocarditis in Adolescents (August 2021)

[2] SARS-CoV-2 Vaccination During Pregnancy: A Complex Decision (April 2021)